Related Experiment Video
Updated: Sep 18, 2025
10:03
Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
5.4K
Soluble CD146 in Heart Failure: Pathophysiological Role and Diagnostic Potential
Daniela Mocan1,2,3,4, Radu Jipa5,6, Daniel Alexandru Jipa7,8
1Multidisciplinary Doctoral School, Vasile Goldis Western University of Arad, 310025 Arad, Romania.
Biomedicines
|June 26, 2025
Summary
Soluble CD146 (sCD146) shows promise as a biomarker for heart failure (HF), reflecting congestion and endothelial stress. However, its clinical use requires standardization due to variability and non-cardiac influences.
Area of Science:
- Cardiology
- Biomarker Discovery
- Vascular Biology
Background:
- Heart failure (HF) is a complex condition with systemic effects.
- Current biomarkers like natriuretic peptides do not fully represent vascular dysfunction in HF.
- CD146 (MCAM) is an endothelial cell glycoprotein involved in vascular processes.
Purpose of the Study:
- To review the structure, regulation, and release of CD146.
- To explore the clinical utility of soluble CD146 (sCD146) as a biomarker in HF.
- To assess sCD146's potential in reflecting hemodynamic congestion and endothelial stress.
Main Methods:
- Literature review synthesizing current knowledge on CD146 and sCD146.
- Analysis of studies associating sCD146 levels with HF indicators and outcomes.
- Evaluation of sCD146's release mechanisms under pathophysiological stimuli.
Main Results:
- Elevated sCD146 levels correlate with congestion indicators (echocardiography, radiology) in HF.
- sCD146 has been linked to adverse outcomes in HF patients.
- sCD146 release is stimulated by endothelial stretch, oxidative stress, and inflammation.
Conclusions:
- sCD146 is a promising biomarker for HF, reflecting congestion and endothelial stress.
- Clinical application is hindered by variability, lack of standardization, and confounding factors like malignancy.
- Further research is needed to standardize sCD146 measurement and clarify its role in HF.
Related Concept Videos
01:29Heart Failure II: Pathophysiology
59
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
59
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
223
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
223
01:17Pathophysiology of Heart Failure
1.9K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.9K
01:30Cardiomyopathy II: Dilated Cardiomyopathy
30
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
30
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
71
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
71
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
353
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
353